United Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio
United Therapeutics (Silver Spring, MD): 4 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $1.23B 2024 CMS Part D & Medicaid spend, and 34 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Silver Spring, MD |
| Reconciled FDA Portfolio Therapies | 4 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2029-01-01 |
| 2024 CMS Total Public Spend | $1.23B |
| 2024 Medicare Part D Spend | $972.7M |
| 2024 Medicaid Spend | $259.8M |
| California HCAI SB 17 Filings | 34 WAC filings (max 19.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for United Therapeutics across sibling Meru public-data platforms.